



UNITED NATIONS

E/NL.1977/53

18 June 1979

ENGLISH ONLY

## LAWS AND REGULATIONS

PROMULGATED TO GIVE EFFECT TO THE PROVISIONS OF  
THE INTERNATIONAL TREATIES ON NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES

BRAZIL

Communicated by the Government of Brazil

NOTE BY THE SECRETARY GENERAL – In accordance with the relevant Articles of the International Treaties on Narcotic Drugs and Psychotropic Substances, the Secretary-General has the honour to communicate the following legislative text.

E/NL.1977/53

Ministry of Health  
National Control Division  
National Medical and Pharmaceutical Control Service

ORDER NO. 26 OF 26 JULY 1974

The Official in Charge of the National Medical and Pharmaceutical Control Service, in exercise of the powers vested in him under article 36 (XX) of the regulations approved in Order No. 304 of 15 October 1970, hereby issues the following instructions on the production, marketing prescription and use of drugs and proprietary pharmaceutical preparations which are capable of causing changes in the higher nervous functions or which require effective and continuous medical supervision owing to the possibility of their inducing undesirable side-effects.

### 1. PRESCRIPTION

1.1. The direct sale to the public of the drugs or proprietary pharmaceutical preparations listed in schedules I and II hereto shall be confined to pharmacies and chemist's shops which are specially licensed for that purpose; it may not take place except on presentation and retention of a prescription made out by a duly qualified practitioner.

1.2. Prescriptions which include the drugs or proprietary pharmaceutical preparations mentioned in paragraph 1.1 may not be dispensed unless:

- (a) They are made out by a duly qualified physician, dental surgeon or veterinarian;
- (b) They are written on a prescription form taken from the practitioner's counterfoil book and giving his name, his registration number in his professional association and the address of his consulting rooms and/or residence;
- (c) They give the full name and address of the patient and directions for use of the medicine prescribed, and bear the date and the autograph signature of the practitioner;
- (d) They are written out legibly in full in Portuguese in ink and in the practitioner's own handwriting;
- (e) The amounts prescribed are given in Arabic numerals and in full;
- (f) The amounts prescribed are also given in the legal units of measurement in force in Brazil;
- (g) In the case of an animal, the prescription states the species, weight and other characteristics, the place where the animal is kept and the name and address of its owner, in addition to the particulars specified under (a), (b), (c) "in fine", (d), (e) and (f) above.

1.3. In cases of emergency and in the absence of the counterfoil book referred to in subparagraph (b) of the foregoing paragraph, the prescription may be written on other paper, provided that the practitioner gives all the relevant details and indicates why the prescription requires urgent attention.

1.4. In public, private or charitable medical or veterinary hospital or parahospital establishments, the medicines listed in the schedules hereto may not be supplied to day patients or out-patients except on a prescription which is written on the headed paper of the establishment by a practitioner who is on the staff of the establishment or can show that he is attending the patient concerned, and which complies in addition with the requirements in paragraph 1.2 of the present Order.

1.5. Only one formulation of any proprietary pharmaceutical preparation listed in the schedules hereto shall appear on each prescription.

1.6. The practitioner signing the prescription shall take full responsibility for the quantity prescribed in it.

1.7. The prescriptions referred to in the present Order shall be valid for 30 (thirty) days from the date on which they are issued.

1.8. Prescriptions by dental surgeons for the proprietary pharmaceutical preparations covered by the present Order shall comply with the provisions of sections I and II of article 6 of Act No. 5,081 of 24 August 1966.

1.9. The maximum prescribable amount of any drug referred to in the present Order shall be the recognized dose to be taken in 72 (seventy-two) hours.

1.9.1. Prescriptions for larger quantities shall bear the prior authorization of the competent supervisory authority.

1.10. Public or private research and/or teaching establishments may make use for those purposes of drugs and proprietary pharmaceutical preparations covered by the present Order provided that the National Medical and Pharmaceutical Control Service has specifically authorized the entire research programme in question.

1.10.1. The drugs and products referred to in the preceding paragraph may not be handled except by such research workers, and on such research premises, as are specified in the programme.

1.10.2. The National Medical and Pharmaceutical Control Service shall forward the appropriate competent organ a copy of the approved research programme for information and examination as required.

## 2. RECORDS

2.1. Industrial pharmaceutical enterprises handling the drugs referred to in the present Order shall record in the appropriate book or other form of record, authenticated by the competent supervisory health authority, all their operations relating to the drugs in question, including the storage of the finished product.

2.2. Pharmacists, chemist's shops, drug wholesalers, representatives and distributors of industrial pharmaceutical enterprises and importers and exporters shall record in the appropriate book or other form of record, authenticated by the competent supervisory health authority, all acquisitions, transactions and sales of the drugs and proprietary pharmaceutical preparations listed in the schedules hereto.

2.3. Prescriptions dispensed for proprietary pharmaceutical preparations covered by the present Order need not be entered in the prescription book where they have already been recorded in the appropriate book or other form of record with sufficient details to identify them in full.

2.4. Where there is an entry in the prescription book, it shall suffice to refer in the appropriate book or other form of record to the number of the entry and the total quantity of units supplied.

2.5. Prescriptions shall be kept on file in chronological order in the establishments concerned for inspection and approval by the competent health authority for 1 (one) year, after which they may be destroyed.

2.6. Hospital establishments (hospitals, nursing homes, clinics and similar institutions) shall record in the appropriate book or other form of record all acquisitions, transactions and uses made of drugs and products to which the present Order refers.

2.6.1. Where the hospital unit does not possess its own dispensary, responsibility for these records shall rest with the director of the establishment as authorized by the local health supervisory body.

2.7. The person in charge of the over-all research programme referred to in paragraph 1.10 shall also be responsible for the control, supervision and recording of the drugs and products authorized for the research in question, in conformity with the instructions and other regulations on the subject at present in force or to be issued in the future; he shall also be required to provide any information requested by the competent health supervisory authority.

2.8. In commercial transactions between industrial firms, traders, hospital and parahospital establishments, teaching establishments and medical assistance organizations, fiscal vouchers shall on issue show clearly and as separate items the names of the drugs or proprietary pharmaceutical preparations subject to the provisions of the present Order, and a copy of each such voucher shall be filed and be available to the health supervisory authorities for a period of 1 (one) year.

2.8.1. Enterprises using mechanized accounting systems shall be at liberty to prepare a daily list of the numbers of the fiscal vouchers relating to the pharmaceutical products subject to the requirements of the present Order, as a substitute for the vouchers themselves.

### 3. LABELLING AND PACKAGING

3.1. The proprietary pharmaceutical preparations listed in schedule II hereto shall be labelled and packaged as follows:

(a) Injectable preparations shall have their name and the composition of the basic component printed on the bottle and be put up in boxes containing 5 (five), 10 (ten) or 15 (fifteen) ampoules or a phial with the corresponding dose when intended for sale to the public, and 25 (twenty-five), 50 (fifty) or 100 (one hundred) when intended for use by hospital and parahospital organizations;

(b) Proprietary pharmaceutical preparations in solid form shall be put up in distinctive packaging for sale to the public in amounts of 20 (twenty) dosage units in the case of tablets, dragées, capsules and pills and in amounts of 5 (five) units in the case of suppositories; when intended for use by hospital and parahospital organizations, they shall be put up in quantities of 50 (fifty), 100 (one hundred) and 200 (two hundred) dosage units;

(c) Proprietary pharmaceutical preparations to be taken orally in the form of powder or granulates shall be put up in distinctive packaging in amounts corresponding in active substance to 10 (ten) or 20 (twenty) tablets when intended for sale to the public, and to 100 (one hundred) tablets when intended for use by hospital and parahospital organizations.

(d) Proprietary pharmaceutical preparations in liquid form to be taken orally shall be put up in quantities of 100 (one hundred) and 200 (two hundred) millilitres and of 20 (twenty) millilitres in the case of dropper containers;

(e) The National Medical and Pharmaceutical Control Service shall be responsible for deciding the quantity which each package of a topical remedy shall contain.

3.2. Proprietary pharmaceutical preparations covered by the present Order and authorized specifically for use as anti-spasmodics may be put up in packages of 100 (one hundred) dosage units for sale to the public and 500 (five hundred) units for hospitals.

3.3. The labels and wrappers of the products listed in the schedules hereto, shall, in addition to meeting the licensing requirements already prescribed, bear the following wording:

"TO BE SOLD ON A MEDICAL PRESCRIPTION WHICH MUST BE SURRENDERED"

3.3.1. Industrial pharmaceutical enterprises shall be allowed 180 (one hundred and eighty) days in which to comply with the provisions of paragraphs 3.1, 3.2 and 3.3.

3.4. In the case of preparations whose labels already bear the wording previously required to the effect that the prescription must be surrendered, failure to comply with paragraph 3.3.1 of the present Order shall not constitute an infringement of that paragraph.

3.5. Manufacturers of proprietary pharmaceutical preparations which now fall for the first time in the category of preparations subject to surrender of prescription on sale shall notify the National Medical and Pharmaceutical Control Service and the corresponding State, territorial, or federal district organ, according to their location, of the number of the last batch of products placed on sale which do not comply with paragraphs 3.1, 3.2 and 3.3.

### 4. SAMPLES

4.1. Samples of the proprietary pharmaceutical preparations covered by the present Order may not be distributed except under the supervision of the competent federal, State and territorial health authorities and in the following circumstances:

(a) Where specifically ordered by a physician, dental surgeon or veterinarian on a prescription form taken from the practitioner's counterfoil book and bearing the date and his autograph signature, up to a maximum of four regulation packages of samples per order;

(b) For clinical purposes, in hospital and parahospital establishments, on the responsibility of a qualified practitioner and as part of a specific programme authorized by the director of the establishment with the prior approval of the National Medical and Pharmaceutical Control Service.

4.2. Labels and wrappers of samples shall clearly bear the following wording:

"PRODUCT SUBJECT TO RESTRICTED SALE AND USE"

4.3. Industrial pharmaceutical enterprises and other establishments which distribute samples of the proprietary pharmaceutical preparations covered by the present Order shall record such operations in the appropriate book or other form of record.

4.3.1. Vouchers evidencing distribution of samples shall be retained by the distributing establishment for a period of 1 (one) year for verification and approval by the competent health authority.

4.3.2. The fiscal consignment voucher shall serve as a return voucher of proof if duly signed by the medical practitioner, dental surgeon or veterinarian.

4.4. Industrial pharmaceutical enterprises shall be allowed 90 (ninety) days in which to comply with the provisions relating to the distribution of samples.

## 5. GENERAL PROVISIONS

5.1. The National Medical and Pharmaceutical Control Service and the corresponding State, territorial or federal district health authority shall be notified whenever the manufacture and sale of products subject to the present Order begins or ends; the notification shall include the number of the last batch manufactured and take place within 30 (thirty) days after the cessation of manufacture or sale.

5.2. Failure to comply with the present Order shall be a health offence under Decree Law No. 785 of 25 August 1969 and be subject to the penalties therein provided.

5.2.1. Persons who in any way assist in committing the above offence or who profit from it shall be jointly and severally liable for the offence.

5.3. In the event of the bankruptcy or judicial liquidation of any establishment manufacturing or selling drugs or proprietary pharmaceutical preparations covered by the present Order, the judicial authority shall give notice to the competent health authority to receive on deposit any stocks taken into safe keeping or forming part of the liquidation assets.

5.4. Any sale by judicial auction of the substances or proprietary pharmaceutical preparations listed in the schedules hereto shall take place in the presence of representatives of the National Medical and Pharmaceutical Control Service or related health organs empowered by the Service, and bidding shall be confined to enterprises or establishments lawfully authorized by the competent health authority.

5.5. The provisions of the present Order shall also apply to products without a trade name which are licensed or authorized by the National Medical and Pharmaceutical Control Service.

5.6. Advertisements for the drugs listed in schedule I hereto and for proprietary preparations containing them may not appear except in technical and scientific journals or publications strictly intended for physicians, veterinarians and, as the case may be, dental surgeons.

5.7. Industrial pharmaceutical enterprises holding licences for proprietary pharmaceutical preparations which are not mentioned in schedule II but contain drugs listed in schedule I hereto shall within 30 (thirty) days inform the National Medical and Pharmaceutical Control Service of the name of the preparation concerned, the corresponding process number and the number and date of the licence, whether or not the product has been manufactured and placed on sale.

5.8. For the purposes of the present Order, "appropriate book" is a book conforming to specimen No. 2 of the General Instructions on the Use and Marketing of Narcotic Drugs and "other form of record" is any separate copy of the wording of a sheet of that book.

5.9. The drugs and proprietary pharmaceutical preparations listed in schedules I and II hereto shall be kept under the strict control of the pharmacist or person in charge of the establishment concerned.

5.10. Schedules I and II hereto are hereby approved.

5.11. Orders No. 5/69 (text and schedule I), 21/69, 28/69 (text), 30/69, 31/69, 32/69, 38/69, 3-70, 3-71, 18-71, 19-71 and 24-71 are hereby repealed.

5.12. The provisions of the present Order shall apply to the proprietary pharmaceutical preparations listed in schedule II to Order No. 5/69 and in the instruments supplementing that Order and to other similar preparations whose licences require them to be sold on surrender of a medical prescription.

5.13. The present Order shall come into force on the date of its publication.

Dagoberto M. de M. Chaves  
Official in Charge, National Medical  
and Pharmaceutical Control Service

## SCHEDULE I TO ORDER NO. 26-74

## Substances

<u>Acepromazine</u> <sup>1/</sup>	<u>Fenproporex</u>	<u>Oxypertine</u>
<u>Amfepramone</u> (diethylpropion)	<u>Flupentixol</u>	Papaverine diethylbarbiturate
<u>Amitriptyline</u>	<u>Fluphenazine</u>	<u>Penfluridol</u>
<u>Azacyclonol</u>	<u>Flurazepam</u>	<u>Perphenazine</u>
<u>Benactyzine</u>	<u>Glutethimide</u>	<u>Periciazine</u> (propericiazine)
<u>Benzocetamine</u>	<u>Haloperidol</u>	Phacetoperane (levophacetoperane)
<u>Benzquinamide</u>	<u>Halothane</u>	<u>Phenaglycodol</u>
Beta-piperonyl-isopropyl-hydrazine	<u>Homofenazine</u>	<u>Phenelzine</u>
<u>Biperiden</u>	Hydrochlorbenzethylamine	<u>Pheniprazine</u>
<u>Bromazepam</u>	Hydroxydione sodium	<u>Phenprobamate</u>
<u>Butaperazine</u>	<u>Imiclopazine</u>	Phenylpropanolamine
<u>Butriptyline</u>	<u>Imipramine</u>	Phthalimidoglutarimide (thalidomide)
<u>Captodiamine</u>	Imipramine N-oxide	<u>Pimozide</u> (R 6238)
Chloral betaine	<u>Iproclozide</u>	<u>Pipamperone</u>
Chloral hydrate	<u>Isocarboxazid</u>	<u>Pipradrol</u>
<u>Chlordiazepoxide</u>	Isopropyl-crotonyl-urea	<u>Prazepam</u>
Chlorhexadol	<u>Ketamine</u>	Prochlorperazine
Chlorimipramine	<u>Levomepromazine</u>	<u>Promazine</u>
Chlorpromazine	<u>Lorazepam</u>	<u>Propanidid</u>
<u>Chlorprothixene</u>	<u>Maprotiline</u>	<u>Propiomazine</u>
<u>Clonazepam</u>	<u>Mecloqualone</u>	<u>Prothipendyl</u>
Clothiapine	<u>Medazepam</u>	<u>Protriptyline</u>
<u>Cyclarbamate</u>	<u>Mefenorex</u>	Quinidine phenylbarbiturate
Cyclexedrine	Mepazine	<u>Sulpiride</u>
<u>Deanol aceglumate</u>	<u>Mephenoqualone</u>	<u>Temazepam</u>
<u>Deanol acetamidobenzoate</u> (DMAE)	<u>Meprobamate</u>	Tetrachloroethylene
N-demethyldiazepam	<u>Mesoridazine</u>	<u>Thiopropazine</u>
<u>Desipramine</u>	<u>Methaqualone</u>	<u>Thioridazine</u>
<u>Dextropropoxyphene</u>	<u>Methocarbamol</u>	Thiotixene
<u>Diazepam</u>	<u>Methopromazine</u>	<u>Tranlycypramine</u>
<u>Dibenzepin</u>	<u>Methoxyflurane</u>	<u>Trazodone</u>
Diethylamine phenylbarbiturate	<u>Methylpentynol</u>	<u>Trichloroethylene</u>
Dimetracrine	<u>Methypylon</u>	<u>Triclofos</u>
Dixyrazine	<u>Methysergide</u>	<u>Trifluoperazine</u>
<u>Doxepin</u>	<u>Moperone</u>	<u>Trifluoperidol</u>
<u>Droperidol</u>	<u>Nialamide</u>	<u>Triflupromazine</u>
<u>Ectylurea</u>	<u>Nitrazepam</u>	<u>Trihexyphenidyl</u>
<u>Emylcamate</u>	<u>Nomifensine</u>	<u>Trimipramine</u>
Ethchlorvynol	<u>Nortriptyline</u>	
<u>Ethinamate</u>	<u>Noxipityline</u>	
Ethyl chloride	<u>Opipramol</u>	
<u>Fencamfamin</u>	<u>Oxazepam</u>	
<u>Fenfluramine</u>	<u>Oxyfenamate</u>	

<sup>1/</sup> Note by the Secretariat: International non-proprietary names are underlined.

## SCHEDULE II TO ORDER NO. 26-74

Abistil	Bloq
Abulemin	Butial
Abulemin AP	Byrofen
Abulempax AP	Calmarian
Adipenan	Calmin
Adrepress	Calmine
Adumbran	Calmix
Aflitil	Calmociteno
Agedal	Calmogen
Akineton	Calmovita
Akneton Retard	Calude
Alertin	Carbam
Aletan	Catron
Algafan (injectable solution)	<u>Chlordiazepoxide</u> - any pharmaceutical form or manufacturer
Alival	
<u>Amfepramone</u> - any pharmaceutical form or manufacturer (diethylpropion)	<u>Chlorpromazine</u> - any pharmaceutical form or manufacturer
Amplietil	Clonix
Amprazin	Clorium
Anafranil	Clorprazin
Anatensol	Clorprasin - simple
Anatensol Depot	Concoordin
Anatensol P	Corpobel
Anatrium	Corporex
Angustil	Cosmorax
Anobesina	Cosmosedin
Anograx	Covatin
Anosedil	Cuiat-D
Ansiar	Cuait-N
Ansiepax	Daforin
Ansiex	Dalmodorm
Ansiolax	Dardanin
Ansiolin	Deastil
Ansiolon	Dedalen
Ansiopan	Delgar
Ansiotex	Deprex
Apex	Depromal
Artane	Deseril
Astress	Desobesi
Azepin	Desobesi M
Belupan	Despertil
Bendialix	<u>Dextropropoxyphene</u> - any pharmaceutical form or manufacturer
Bensofepin	
Beta-Clor	Dialor
Biostil	Diamicil
Biotrol	Dianorex
	Diapason

Diatrex	Evadyne
Diatrex AP	Eventin
Diazelin	Farmoglan
Diazelong	Fastinan
<u>Diazepam</u> - any pharmaceutical form or manufacturer	Fastinan AP
Diazetard	Fatinil
Dienpax	Fatinil AP
Dienpax AP	<u>Fencamfamine</u> - any pharmaceutical form or manufacturer
Diepin	Fenidex
Diestren	Fenidex AP
Dietex	Fenorex
<u>Diethylpropion</u> tablets ("Paulifarma")	Fenorex AP
Dimagrin	<u>Fenproporex</u> - any pharmaceutical form or manufacturer
Dinamagra AP	Fenproxin
Dipiperon	Fidepax
Ditisan	Flobesin
Dobesix LP	Fluothane
Dogmalid	Flupsixol
Dogmatil	Flurazepol
Doloxene (injectable solution)	Fomenon
Doloxone H (injectable solution)	Fortzepam
Dominal	Frenafom
Dorevane	Frenquel
Doriden	Frumidan
Dormex	Gamafenil
<u>Doxepin</u> - any pharmaceutical form or manufacturer	Gamaquil
Drimuel	Gardenal
Droperidol	Gardenal for children
Enlonyl	Gardenalinas
Elegatin	Gentaplexin
Elepsin	Gulastop
Elmonal	Haloperidol
Elmonal gel	<u>Halothane</u>
Emagrecil	<u>Halothane</u> - Ayerst liquid anaesthetic
Emagril	Hartol
Emagrin	Hastil
Emotil	Helmitan
Empax	Hibinil
Epilpax	Hidropan
Equilid	Hipnax
Equilipan	Hipofagin
Ergotonil	Horminal
Esbeltina	Hypnolon
Esbeltrat	Ifag
Esucos	<u>Imipramine</u> - any pharmaceutical form or manufacturer
Etumine Wander	Imipraz
Euforil	

Indenil  
 Indunox  
 Inibex  
 Inobesin  
 Inobesin AP  
 Insidon  
 Insonium  
 Isodepril  
 Izoazina  
 Jesal  
 Kalmoxil  
 Kazepan  
 Kelene  
 Ketalar  
 Kiatrium  
 Kondoxan  
 Lepenil  
 Levanxol  
 Levil  
 Levil for children  
 Lexotan  
 Lexotan - suspension for children  
 Librioum  
 Lidanar  
 Lidepran  
 Limbritol  
 Linopen  
 Linopen AP  
 Lipenan AP  
 Lipese  
 Lipex  
 Lipidin  
 Lipoclase  
 Lipoclasse  
 Lipoclasse AP  
 Lipoex  
 Lipogen  
 Lipograssil  
 Lipolin  
 Lipolin AP  
 Lipolisine  
 Lipolisine AP  
 Lipomax  
 Lipomax AP  
 Lipoplex  
 Liporex  
 Liporexin  
 Lipostil

Lipostil AP  
 Lipovita  
 Lipovita AP  
 Lipozid  
 Liprorrex  
 Lisalipol  
 Lisemex  
 Lisozepan  
 Listica  
 Lorax  
 Lorazam  
Lorazepam - any pharmaceutical form  
 or manufacturer  
 Lorenpax  
 Loril  
 Lotawin  
 Ludiomil  
 Luminal  
 Luminaletas  
 Lunipax  
 Luzepin  
 Medalen  
 Madar  
 Magrene  
 Magress  
 Majeptil  
 Mandrix  
 Marplon  
 Maxipaz  
 Maxizepan  
 Medaciteno  
 Medalium  
 Medazen  
Medazepam - any pharmaceutical form or  
 manufacturer  
 Medazepol  
 Medazepol AP  
 Medazon  
 Melleril  
 Melleril for children  
 Melleril - 200 Retard  
 Melpazil  
 Meprobal  
Meproamate - any pharmaceutical form or  
 manufacturer  
 Meprofenil  
 Meprolen  
 Mepromax  
 Meproneuran



Meproneuran with phenobarbital	Neozine for children
Meprosan	Nervium
Meprosay	Neuleptil
Meprosedan	Neuleptil for children
Meprosin	Neurap
Meprosin for children	Neurazon
Mequalon	Neuriplex
Messapia	Neuritex
Metagen	Neurium
Metarelay	Neurocontrol
Metolil	Neurominal
Metdil A	Neuroplegine
Metolil S	Neurozulin
Metolil T	Niamid
Mezapan	Niamid Parenteral in powder form
Miltown	Nilipoid AP
Minifage	Nirvalene
Ministan	<u>Nitrazepam</u> - any pharmaceutical form or manufacturer
Miolaxene	Nitrazepol
Modelin	Nitrenpax
Miorel	Niveltress
Miorrelax	Niveltress Retard
Moderafom	Noan
Moderakid	Noan AP
Moderamin	Noadsied
Moderan AP	Nobese
Moderape e AP	Nobrium
Moderasin	Noctazepam
Moderat	Noludar
Moderex	Norexil
Moderil	Norexon
Moderine	Norexon Retard
Modecyr	Notaral
Modulan	Novapirid
Mogadon	Novazepam
Motival dragées ("Filmlok")	Noveril Wander
Motivina	Nubarene
Muconil	Oasil-Simes
Mutabon	Obelex
Mutabon A	Obenil
Mutabon D	Obesitol
Nardil	Obesonon
Natishedine	Obex
Navane	Oblivon
Negatan	Odocilin
Negatan AP	Onirium
Neostress	Orap
Neozine	

Oxabril	Psicopax
Oxatrat	Psicoplex
Oxazelin	Psicossedin
<u>Oxazepam</u> - any pharmaceutical form or manufacturer	Psicossedin - 5 mg - for infants
Oxazepol	Psiquium
Pacatal	Quantril
Pacienx	Quetil
Pacintran (long-lasting effect)	Quipax
Pacintran N (long-lasting effect)	Randolectil
Pacintran DN (long-lasting effect)	Raupentin
Pansedans	Redulip
Pantogenina	Redux
Parnate	Redufome
Paseden	Regim
Paxate	Regi-men
Paxton	Relaxan
Pentrane	Relaxil
Perphenazine - any pharmaceutical form or manufacturer	Relax-Pam
Pertofran	Repesan
Pesex	Reprimil
Pesex AP	Reverax
Pesonex	Revonal
<u>Phenobarbital</u> - any pharmaceutical form or manufacturer	Rivotril
Phthalimidoglutarimide - any pharmaceutical form or manufacturer ( <u>thalidomide</u> )	Robaxin
Placimin	Samida de Angeli
Plaxana	Saninger
Plegicil	Sedacalm
Ponderex	Sedavier
Ponderex AP	Sedax
Ponderil	Sedolin
Pondinol "Roche"	Sedomepril
Ponil	Sedotex
Ponsital	Semap
Prolinan	Serenex
Promazionon	Serenium
Promilene	Sevinol
Propiofen	Sevinol Reptabs
Proporex	Sicomatil
Proporex AP	Siledin
Proteuforil	Sinequan
Prozepin	Sintomax
Psicobione	Sintonan
Psicodin	Siplarol
Psicofar	Siquil
Psicolatil	Sofrosine
	Sonebon
	Sonex
	Sonin

Sonipam	<u>Trihexyphenidyl</u> - any pharmaceutical form or manufacturer
Sonium	
Sonoasil	Trilafon
Sonobel	Trilafon Reptabs
Sonopax	Trilene
Sonotal	Triperidol
Sonotrat	Tryptanol
Stabilin	Ultrazepam
Stelapar No. 1	Usempax
Stelapar No. 2	Usempax - long-lasting effect
Stelazine	Vagonal
Stenorol	Valium
Striatan C	Vate
<u>Sulpiride</u> - any pharmaceutical form or manufacturer	Vermucina
Sulpiril	Viadril
Sultranquin	Vividyl
Suprefon	Vividyl (nortriptylene hydrochloride, Lilly)
Surmontil	Zepanil
Tacital	Zepased
Takan	
Tementil	
Temiran	
Temiran Dospan	
Tempase	
Tensil	
Tensobel	
Tensocron	
Tensolisin	
Tenzepam	
<u>Tetrachloroethylene</u> - any pharmaceutical form or manufacturer	
Tofranil	
Tombran	
Trancalmat	
Tranil	
Tranquix	
Tranquil	
Tranquilase	
Tranquilid	
Tranquilin	
Tranquimax	
Tranquisan	
Tranquix	
Tranxilene	
Tricioryl	
<u>Trifluoperazine</u> - any pharmaceutical form or manufacturer	
<u>Triflupromazine</u> - any pharmaceutical form or manufacturer	